MIKKO PUHAKKA

Yhteystiedot

Julkaisut

• Kautiainen K, Ekroos H, Puhakka M, Liira H, Laine J, Linden K, Hahl J. 2016. Re-treatment with varenicline is a cost-effective aid for smoking cessation. JOURNAL OF MEDICAL ECONOMICS 2017; 20 3: 246-252. 2016
• Maeng M, Holm NR, Erglis A, Kumsars I, Niemelä M, Kervinen K, Jensen JS, Galløe A, Steigen TK, Wiseth R, Narbute I, Gunnes P, Mannsverk J, Meyerdierks O, Rotevatn S, Nikus K, Vikman S, Ravkilde J, James S, Aarøe J, et al. (including Puhakka M). 2013. Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: nordic bifurcation study 5-year follow-up results. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 62 1: 30-34. 2013
• Scholte op Reimer W, de Swart E, de Bacquer D, Pyörälä K, Keil U, Heidrich J, Deckers JW, Kotseva K, Wood D, Boersma E, for the EUROASPIRE Investigators, Lehto S, Lehto R, Koukkunen H, Puhakka M, Savolainen K. 2006. Smoking behaviour in European patients with established coronary heart disease. EUROPEAN HEART JOURNAL 27: 35-41. 2006
• Puhakka M, Magga J, Hietakorpi S, Penttilä I, Uusimaa P, Risteli J, Peuhkurinen K. 2003. Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation. JOURNAL OF CARDIAC FAILURE 9 4: 325-332. 2003
• EUROASPIRE II Study Group, Lehto S, Puhakka M, Pyörälä K, Kärkkäinen S, Lehto R. 2001. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme. EUROPEAN HEART JOURNAL 22: 554-572. 2001